Study shows Cinryze (Viro Pharma) effective for long-term treatment of Hereditary Angio-oedema

New results demonstrate that routine prophylactic use of Cinryze (C1 esterase inhibitor), from Viro Pharma, provided effectiveness and maintained a generally favorable safety profile in the majority of treated subjects with Hereditary Angio-oedema. Treated with Cinryze 1000 units every 3 to 7 days, subjects experienced a 93.7 percent reduction in attacks while taking prophylactic Cinryze (median of 0.19 attacks per month) compared with the median historical rate at baseline (3 attacks per month). Some 87.7 percent reported an attack frequency of one or less attack per month during prophylactic Cinryze and 34.9 percent had no attacks during the study. Some 7.5 percent of subjects experienced relatively frequent attacks despite twice-weekly Cinryze.

Additionally, though 18 subjects (12.3 percent) had an overall attack rate of more than 1 per month on Cinryze. The efficacy of Cinryze directly correlated with the interval between injections. No subjects discontinued the study drug because of an adverse event. Eighty-six percent of treatment-emergent adverse events were of mild or moderate intensity.

"The results of this study reinforce the efficacy and safety profile of Cinryze when used up to 2.6 years." says Bruce L. Zuraw, professor of medicine and program director of the Allergy and Immunology Fellowship Program at the University of California at San Diego, lead author in a paper published in the July 14th online edition of The American Journal of Medicine.